Humacyte, Inc.
Clinical trials sponsored by Humacyte, Inc., explained in plain language.
A biotech company developing bioengineered human tissues and organs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Lab-Made blood vessel could free dialysis patients from catheters Results expected Jun 2027 (estimated) May already have reported ↗
-
Desperate patients get access to experimental Lab-Made vessel
Disease control Expanded access (paused)This program allows individual patients with vascular disease or end-stage kidney disease on dialysis to request an experimental lab-grown blood vessel (ATEV) if they have no other treatment options and cannot join a clinical study. The vessel is designed to replace or bypass dam…
Sponsor: Humacyte, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Lab-Made blood vessel could free dialysis patients from catheters
Disease control OngoingThis Phase 3 trial tests a lab-grown blood vessel (ATEV) against the standard surgically created fistula in 121 women with end-stage kidney disease who need dialysis. The goal is to see if the ATEV allows more days without a catheter and reduces infections over 12 months. If succ…
Phase 3 • Sponsor: Humacyte, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC